Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai, Lei He, Xiujuan Zhang, et al.
Cellular and Molecular Immunology (2020) Vol. 17, Iss. 6, pp. 613-620
Open Access | Times Cited: 1696

Showing 1-25 of 1696 citing articles:

The trinity of COVID-19: immunity, inflammation and intervention
Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 6, pp. 363-374
Open Access | Times Cited: 4293
Immunology of COVID-19: Current State of the Science
Nicolas Vabret, Graham J. Britton, Conor Gruber, et al.
Immunity (2020) Vol. 52, Iss. 6, pp. 910-941
Open Access | Times Cited: 1654
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech, Gary Albert, Iksung Cho, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 24, pp. 2320-2332
Open Access | Times Cited: 1160
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
Indwiani Astuti, Ysrafil Ysrafil
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 4, pp. 407-412
Open Access | Times Cited: 1065
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Shibo Jiang, Christopher D. Hillyer, Lanying Du
Trends in Immunology (2020) Vol. 41, Iss. 5, pp. 355-359
Open Access | Times Cited: 913
Biomarkers associated with COVID-19 disease progression
Giovanni Ponti, Monia Maccaferri, Cristel Ruini, et al.
Critical Reviews in Clinical Laboratory Sciences (2020) Vol. 57, Iss. 6, pp. 389-399
Open Access | Times Cited: 854
COVID-19 Vaccine: A comprehensive status report
Simran Kaur, Vandana Gupta
Virus Research (2020) Vol. 288, pp. 198114-198114
Open Access | Times Cited: 850
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Hongjing Gu, Qi Chen, Guan Yang, et al.
Science (2020) Vol. 369, Iss. 6511, pp. 1603-1607
Open Access | Times Cited: 776
COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection
Stephany Beyerstedt, Expedito Barbosa Casaro, Érika Bevilaqua Rangel
European Journal of Clinical Microbiology & Infectious Diseases (2021) Vol. 40, Iss. 5, pp. 905-919
Open Access | Times Cited: 716
Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
Luis F. García
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 657
COVID-19: A promising cure for the global panic
Balachandar Vellingiri, Kaavya Jayaramayya, Mahalaxmi Iyer, et al.
The Science of The Total Environment (2020) Vol. 725, pp. 138277-138277
Open Access | Times Cited: 635
A Thermostable mRNA Vaccine against COVID-19
Na-Na Zhang, Xiao-Feng Li, Yong‐Qiang Deng, et al.
Cell (2020) Vol. 182, Iss. 5, pp. 1271-1283.e16
Open Access | Times Cited: 609
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Gregory A. Poland, Inna G. Ovsyannikova, Richard B. Kennedy
The Lancet (2020) Vol. 396, Iss. 10262, pp. 1595-1606
Open Access | Times Cited: 604
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
Chunyan Yi, Xiaoyu Sun, Jing Ye, et al.
Cellular and Molecular Immunology (2020) Vol. 17, Iss. 6, pp. 621-630
Open Access | Times Cited: 503
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
Katharina Röltgen, Abigail E. Powell, Oliver F. Wirz, et al.
Science Immunology (2020) Vol. 5, Iss. 54
Open Access | Times Cited: 469
Drug repurposing approach to fight COVID-19
Thakur Uttam Singh, Subhashree Parida, Madhu Cholenahalli Lingaraju, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 6, pp. 1479-1508
Open Access | Times Cited: 452
The COVID-19 pandemic: a global health crisis
Casey Pollard, Michael P. Morran, Andrea L. Nestor‐Kalinoski
Physiological Genomics (2020) Vol. 52, Iss. 11, pp. 549-557
Open Access | Times Cited: 432
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens
Liangwei Duan, Qianqian Zheng, Hongxia Zhang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 403
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 384
Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
Jianhui Nie, Qianqian Li, Jiajing Wu, et al.
Nature Protocols (2020) Vol. 15, Iss. 11, pp. 3699-3715
Open Access | Times Cited: 383
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Jiří Zahradník, Shir Marciano, Maya Shemesh, et al.
Nature Microbiology (2021) Vol. 6, Iss. 9, pp. 1188-1198
Open Access | Times Cited: 377
Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition
Oliver C. Grant, David W. Montgomery, Keigo Ito, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 370
Immune-mediated approaches against COVID-19
Helena F. Florindo, Ron Kleiner, Daniella Vaskovich‐Koubi, et al.
Nature Nanotechnology (2020) Vol. 15, Iss. 8, pp. 630-645
Open Access | Times Cited: 334
ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
Natalia Zamorano Cuervo, Nathalie Grandvaux
eLife (2020) Vol. 9
Open Access | Times Cited: 318
Sex differences in severity and mortality from COVID-19: are males more vulnerable?
Ajay Pradhan, Per‐Erik Olsson
Biology of Sex Differences (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 288
Page 1 - Next Page

Scroll to top